RBC’s New Outperform Rating for AbbVie (ABBV) Stock: Investor Implications

Posted on by

TLDR

  • RBC Capital Markets initiated coverage of AbbVie (ABBV), assigning an outperform rating and a $260 price target, which suggests approximately 14% potential upside.
  • Analyst Trung Huynh contends that worries regarding AbbVie’s growth trajectory are exaggerated, highlighting Skyrizi and Rinvoq as primary contributors.
  • According to RBC, AbbVie faces no immediate loss of exclusivity (LOE) challenges and has no requirement for mergers and acquisitions (M&A).
  • Trading at less than 16 times earnings, ABBV’s valuation is more akin to pharmaceutical counterparts dealing with LOEs than to rapidly growing companies such as Eli Lilly.
  • AbbVie also disclosed a $380 million investment for constructing two new active pharmaceutical ingredient (API) manufacturing plants in North Chicago, anticipating 300 new job creations.

On February 25, 2026, RBC Capital Markets commenced coverage of AbbVie (ABBV), issuing an outperform rating and setting a price target of $260.

ABBV Stock Card

This target implies an approximate 14% upside from AbbVie’s closing price on February 24.

Analyst Trung Huynh challenged the dominant pessimistic view surrounding the stock. He asserted that critics were mistaken in declaring that “the beat-and-raise narrative has concluded.”

Huynh specifically identified Skyrizi and Rinvoq as central to his argument. He stated that both medications are still undergoing “early indication expansion,” suggesting a longer growth trajectory than the market currently seems to account for.

AbbVie also faces no immediate loss of exclusivity concerns for its existing portfolio of drugs. This provides a significant advantage in an industry where patent expirations can rapidly erode billions in revenue.

Huynh further observed that AbbVie is not compelled to pursue acquisitions. The absence of M&A pressure translates to reduced balance sheet risk and enhanced predictability for shareholders.

Regarding valuation, he drew a sharp contrast. With a price-to-earnings ratio below 16x, ABBV’s trading multiple resembles that of Merck — a company contending with LOE challenges — rather than a high-growth entity like Eli Lilly.

This is despite AbbVie achieving approximately 17% EPS growth, in contrast to about 6% for its competitors. Huynh characterized its PEG valuation as more appealing than Lilly’s.

Catalysts Ahead in 2026

Huynh outlined a packed schedule of potential catalysts. Rinvoq is anticipated to have three catalysts this year, and Skyrizi two.

The FDA is also expected to issue a decision on tavapadon for Parkinson’s disease. This ruling could represent a significant short-term event for the company’s stock.

AbbVie is also slated to publish Phase 1 data for ABBV-295, a long-acting amylin analogue aimed at obesity. While the field of obesity drug development is competitive, initial data could still influence market sentiment.

Phase 3 data for Lutikizumab in hidradenitis suppurativa is another upcoming announcement.

Manufacturing Expansion Adds Long-Term Depth

In a separate development, AbbVie declared a $380 million investment for the construction of two new API manufacturing facilities at its North Chicago, Illinois site.

Construction is scheduled to commence in spring 2026, with both facilities projected to be operational by 2029.

These facilities will concentrate on next-generation neuroscience and obesity medications, employing advanced manufacturing technologies and artificial intelligence.

AbbVie intends to recruit 300 new employees to support this expansion, filling positions in engineering, science, manufacturing operations, and laboratory functions.

CEO Robert A. Michael described this as “additional progress” toward the company’s previously stated $100 billion commitment to U.S. R&D and capital investment over the coming decade.

This initiative follows a groundbreaking in September 2025 for a distinct chemical synthesis facility, also intended to bring API production back to the U.S.

RBC’s $260 price target represents the most recent analyst recommendation for the stock, issued on February 25, 2026.